STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNPX
  4. [DEF 14A] Genprex, Inc. Definitive Proxy Statement

[DEF 14A] Genprex, Inc. Definitive Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
DEF 14A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GNPX logo
Genprex Inc

NASDAQ:GNPX

GNPX Rankings

#6287 Ranked by Market Cap
N/A Ranked by Dividends

GNPX Latest News

Sep 2, 2025
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Aug 18, 2025
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Aug 4, 2025
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Jun 24, 2025
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 23, 2025
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

GNPX Latest SEC Filings

Aug 20, 2025
[8-K] Genprex, Inc. Reports Material Event
Aug 18, 2025
[8-K] Genprex, Inc. Reports Material Event
Aug 15, 2025
[8-K] Genprex, Inc. Reports Material Event
Aug 5, 2025
[RW] Genprex, Inc. SEC Filing
Aug 4, 2025
[8-K] Genprex, Inc. Reports Material Event

GNPX Stock Data

7.95M
42.79M
0.33%
2.23%
8.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN